Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16882108rdf:typepubmed:Citationlld:pubmed
pubmed-article:16882108lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0948265lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C1620263lld:lifeskim
pubmed-article:16882108lifeskim:mentionsumls-concept:C1635037lld:lifeskim
pubmed-article:16882108pubmed:issue4lld:pubmed
pubmed-article:16882108pubmed:dateCreated2006-8-2lld:pubmed
pubmed-article:16882108pubmed:abstractTextMetformin is considered the gold standard for type 2 diabetes treatment as monotherapy and in combination with sulphonylureas and insulin. The combination of metformin with thiazolidinediones is less well studied. The aim of the present study was to assess the differential effect, and tolerability, of metformin combined with pioglitazone or rosiglitazone on glucose, coagulation and fibrinolysis parameters in patients with type 2 diabetes mellitus and metabolic syndrome.lld:pubmed
pubmed-article:16882108pubmed:languageenglld:pubmed
pubmed-article:16882108pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:citationSubsetIMlld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16882108pubmed:statusMEDLINElld:pubmed
pubmed-article:16882108pubmed:monthAuglld:pubmed
pubmed-article:16882108pubmed:issn0269-4727lld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:FerrariIIlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:D'AngeloAAlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:GravinaAAlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:MontagnaLLlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:CiccarelliLLlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:DerosaGGlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:CiceroA F GAFlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:PiccinniM NMNlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:RagonesiP DPDlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:PricoloFFlld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:SalvadeoS A...lld:pubmed
pubmed-article:16882108pubmed:authorpubmed-author:PanigaSSlld:pubmed
pubmed-article:16882108pubmed:issnTypePrintlld:pubmed
pubmed-article:16882108pubmed:volume31lld:pubmed
pubmed-article:16882108pubmed:ownerNLMlld:pubmed
pubmed-article:16882108pubmed:authorsCompleteYlld:pubmed
pubmed-article:16882108pubmed:pagination375-83lld:pubmed
pubmed-article:16882108pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:meshHeadingpubmed-meshheading:16882108...lld:pubmed
pubmed-article:16882108pubmed:year2006lld:pubmed
pubmed-article:16882108pubmed:articleTitleMetformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.lld:pubmed
pubmed-article:16882108pubmed:affiliationDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. giuseppe.derosa@unipv.itlld:pubmed
pubmed-article:16882108pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16882108pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16882108pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16882108lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16882108lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16882108lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16882108lld:pubmed